When it comes making a difference in people’s lives, it’s not about how many medicines you have, but having the ones that work, says PHARMAC Chief Executive Steffan Crausaz.
PHARMAC has announced a major funding package with Roche for nine medicines covering ten different conditions.
The 2016/17 annual tender has been released and PHARMAC is inviting suppliers to submit bids on over 500 products by 15 December 2016.
PHARMAC is pleased to announce a new partnership to support prescribing decisions and promote the responsible use of medicines, says PHARMAC Deputy Medical Director, Dr Bryan Betty.
PHARMAC helps New Zealanders live healthier and better lives, everyday.
PHARMAC is entering a new phase of its national hospital medical device contracting, as it implements the first market share contracts for a set of wound care products.
Steffan Crausaz, PHARMAC Chief Executive, would like to take the time to wish pharmacists from all over New Zealand #happyworldpharmacistsday for Sunday 25 September.
PHARMAC is asking New Zealanders to help it make some changes to how medicine and medical device funding applications are made.
PHARMAC’s decisions affect nearly all New Zealanders, and the Government pharmaceutical funding agency is asking people to help it make some changes to how medicine and medical devices funding applications are made.
PHARMAC’s Consumer Advisory Committee has new leadership and new members.
PHARMAC is pleased to announce the funding of pembrolizumab, following successful commercial negotiations and evolution in evidence, says PHARMAC Director of Operations, Sarah Fitt.
PHARMAC has today announced changes to funded vaccines, which will benefit an extra 100,000 people, says PHARMAC Director of Operations Sarah Fitt.
After listening to what New Zealanders had to say, PHARMAC has changed the way it makes decisions - the most significant change to its decision making in its 23 year history.
New data from PHARMAC is predicting DHB hospital spending on surgical and medical devices will fall by about $25 million over coming years.
PHARMAC has commenced consultation on a proposal to fund pembrolizumab (Keytruda) for advanced melanoma.
PHARMAC has signed a Memorandum of Agreement (MoA) with Te Rūnanga o Aotearoa New Zealand Nurses Organisation.
PHARMAC is today announcing funding of six new treatments across important areas of health, including major advancements in the treatment of hepatitis C. From 1 July...
PHARMAC and the Health Research Council of New Zealand have created a partnership to make more than $400,000 available for pharmaceutical-related health research.
PHARMAC is asking the public for feedback on proposals to widen funding access to the varicella (chickenpox) and human papillomavirus (HPV) vaccines, as well as other changes to funded vaccines.
PHARMAC's new approach to funding medicines for rare disorders is gaining real traction.